email article
Hospitalized COVID-19 patients may safely continue taking their angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), according to the small REPLACE COVID trial.
The study s primary hierarchical endpoint a global rank score in which patients were ranked by the severity of their COVID disease course according to various biomarkers and clinical events, with a lower rank score meaning more severe COVID-19 hospitalization was about the same whether people were randomized to continue or discontinue these common blood pressure medications (median rank 73 vs 81, β-coefficient 8, 95% CI –13 to 29).
Continuation and discontinuation groups also showed no differences in the secondary endpoints of: